JP2010532761A5 - - Google Patents

Download PDF

Info

Publication number
JP2010532761A5
JP2010532761A5 JP2010515262A JP2010515262A JP2010532761A5 JP 2010532761 A5 JP2010532761 A5 JP 2010532761A5 JP 2010515262 A JP2010515262 A JP 2010515262A JP 2010515262 A JP2010515262 A JP 2010515262A JP 2010532761 A5 JP2010532761 A5 JP 2010532761A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
anxiety
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010515262A
Other languages
English (en)
Japanese (ja)
Other versions
JP5775303B2 (ja
JP2010532761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/069085 external-priority patent/WO2009006548A2/en
Publication of JP2010532761A publication Critical patent/JP2010532761A/ja
Publication of JP2010532761A5 publication Critical patent/JP2010532761A5/ja
Application granted granted Critical
Publication of JP5775303B2 publication Critical patent/JP5775303B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010515262A 2007-07-03 2008-07-02 不安に対する治療法 Expired - Fee Related JP5775303B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94789207P 2007-07-03 2007-07-03
US60/947,892 2007-07-03
PCT/US2008/069085 WO2009006548A2 (en) 2007-07-03 2008-07-02 Treatment for anxiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014011009A Division JP2014129353A (ja) 2007-07-03 2014-01-24 不安に対する治療法

Publications (3)

Publication Number Publication Date
JP2010532761A JP2010532761A (ja) 2010-10-14
JP2010532761A5 true JP2010532761A5 (cg-RX-API-DMAC7.html) 2012-08-23
JP5775303B2 JP5775303B2 (ja) 2015-09-09

Family

ID=40226818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010515262A Expired - Fee Related JP5775303B2 (ja) 2007-07-03 2008-07-02 不安に対する治療法
JP2014011009A Pending JP2014129353A (ja) 2007-07-03 2014-01-24 不安に対する治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014011009A Pending JP2014129353A (ja) 2007-07-03 2014-01-24 不安に対する治療法

Country Status (10)

Country Link
US (2) US8008253B2 (cg-RX-API-DMAC7.html)
EP (1) EP2175873B1 (cg-RX-API-DMAC7.html)
JP (2) JP5775303B2 (cg-RX-API-DMAC7.html)
KR (1) KR101604428B1 (cg-RX-API-DMAC7.html)
CN (1) CN101827604B (cg-RX-API-DMAC7.html)
AU (1) AU2008272903B2 (cg-RX-API-DMAC7.html)
CA (1) CA2692412C (cg-RX-API-DMAC7.html)
DK (1) DK2175873T3 (cg-RX-API-DMAC7.html)
ES (1) ES2555172T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009006548A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
AU2013251426A1 (en) * 2012-04-27 2014-11-20 Indiana University Research And Technology Corporation Compositions and methods for treating PTSD and related diseases
JP6229208B2 (ja) 2013-11-05 2017-11-15 三菱ケミカル株式会社 粘着剤組成物
JP6388023B2 (ja) 2014-03-10 2018-09-12 三菱ケミカル株式会社 画像表示装置構成用積層体の製造方法
LT3149048T (lt) * 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
TWI799903B (zh) 2016-02-08 2023-04-21 日商三菱化學股份有限公司 透明雙面黏著片及黏著片積層體
KR102652894B1 (ko) 2016-02-08 2024-04-01 미쯔비시 케미컬 주식회사 투명 양면 점착 시트 및 점착 시트 적층체
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯(北京)生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
CN106632601B (zh) * 2016-11-16 2020-10-20 中国科学院昆明动物研究所 一种阻断突触长时程增强(ltp)的短肽及其应用
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
KR102545825B1 (ko) * 2017-09-30 2023-06-22 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
TW202132325A (zh) * 2019-11-05 2021-09-01 國立大學法人京都大學 胜肽、組成物以及治療、預防或改善情緒障礙之方法
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
CN113735938B (zh) 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723838B1 (en) 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
JP2004501901A (ja) * 2000-06-26 2004-01-22 メルク エンド カムパニー インコーポレーテッド イミノピリミジン系nmdanr2b受容体拮抗薬
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
FI20012082A0 (fi) 2001-10-26 2001-10-26 Paeivi Liesi Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
GB0303613D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
WO2005017203A2 (en) 2003-07-11 2005-02-24 Yale University Systems and methods for diagnosing and treating psychological and behavioral conditions
CN1878551A (zh) 2003-11-12 2006-12-13 默克公司 4-苯基哌啶磺酰基甘氨酸转运体抑制剂
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
US20060216331A1 (en) 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
EP1976502B1 (en) * 2005-12-30 2011-08-03 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8262847B2 (en) * 2006-12-29 2012-09-11 Lam Research Corporation Plasma-enhanced substrate processing method and apparatus
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Similar Documents

Publication Publication Date Title
JP2010532761A5 (cg-RX-API-DMAC7.html)
Zhu et al. Risks associated with misuse of ketamine as a rapid-acting antidepressant
Yousef et al. A double‐blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component
Gan et al. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting
JP2014526441A5 (cg-RX-API-DMAC7.html)
JP2020180141A (ja) 視床皮質律動異常の処置
Liu et al. Sedation effects of intranasal dexmedetomidine combined with ketamine and risk factors for sedation failure in young children during transthoracic echocardiography
US9821023B2 (en) Methods for the treatment of central nervous system (CNS) disorders and mood disorders
Tang et al. The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
Cheng et al. Butorphanol suppresses fentanyl-induced cough during general anesthesia induction: A randomized, double-blinded, placebo-controlled clinical trial
Liu et al. Electroacupuncture attenuates brain injury through α7 nicotinic acetylcholine receptor-mediated suppression of neuroinflammation in a rat model of asphyxial cardiac arrest
Alamy et al. Escitalopram in specific phobia: results of a placebo-controlled pilot trial
JP2007521333A5 (cg-RX-API-DMAC7.html)
Rakhman et al. Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial
US9814755B2 (en) Methods for the treatment of depression and anxiety
Ouchi Dexmedetomidine 2 ppm is appropriate for the enhancement effect of local anesthetic action of lidocaine in inferior alveolar nerve block: a preliminary, randomized cross-over study
US10550157B2 (en) Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
CN110548132B (zh) TGF-β1蛋白在制备治疗抑郁症的药物中的应用
Honarmand et al. A comparison of the effect of pretreatment with intravenous dexamethasone, intravenous ketamine, and their combination, for suppression of remifentanil-induced cough: a randomized, double-blind, placebo-controlled clinical trial
Heidari et al. Geranisetron versus gabapentin in preventing postoperative nausea and vomiting after middle ear surgery in adults: a double-blinded randomized clinical trial study
Abu-Halaweh et al. Pretreatment with remifentanil, fentanyl, or lidocaine to prevent withdrawal after rocuronium using venous occlusion technique in children and adolescents: a prospective randomized placebo-controlled double-blind study
Ladha et al. Sustained mood improvement with laughing gas exposure (SMILE): a randomised, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression
EP4351727A1 (en) Method of treating drug resistant epilepsy
Naik et al. Comparative study of acupressure wristband versus palonosetron for prophylaxis of postoperative nausea and vomiting in elective laparoscopic cholecystectomy under general anaesthesia